Tufts CSDD

Personalized medicine development tied to showing value of companion diagnostics

Monday, August 24, 2015

With interest in personalized medicines growing, drug and diagnostics companies are investing in the development of companion diagnostics that can show that their use in conjunction with personalized therapeutics will lead to positive health outcomes, according to R&D leaders participating in a roundtable recently hosted by the Tufts Center for the Study of Drug Development (CSDD).

[Read More]

Is there really a shortage of study volunteers?

Saturday, August 1, 2015

Patient recruitment remains one of the biggest challenges facing the clinical research enterprise today. Forward-thinking industry leaders recognize the need for rethinking the common view that pa­tient recruitment is difficult primarily due to a shortage of study volunteers. Instead, these experts believe the industry needs to focus the discussion on practices that limit access to clinical trials and how to build support sys­tems needed to better engage patient commu­nities and the public in clinical research.

[Read More]

FDA, TransCelerate, INC Research to speak at 10th Annual Global Site Solutions Summit

Wednesday, June 24, 2015

The Society for Clinical Research Sites (SCRS), a global trade organization representing the interests of clinical research sites, has announced an invigorated, solution-driven program for the 10th Annual Global Site Solutions Summit. The Summit will be Oct. 8-11, in Amelia Island, Fla. The annual meeting, which attracts investigators, site executives and industry executives from around the globe, is inclusive of interactive sessions, knowledge and best practice sharing, and networking opportunities, centered around the collaboration-focused theme “Better Together.”

[Read More]

Pharma industry improves its tarnished reputation

Monday, June 15, 2015

The reputation of the pharmaceutical industry—historically not much better than that of the oil or tobacco industries—has stabilized in recent years. And public views about clinical research have improved significantly. Yet overall, the level of trust in pharmaceutical companies remains low.

[Read More]